Drug intelligence / Profile preview

MaaT-033

Development stage: Phase 3
Lead developer: MaaT Pharma
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

MaaT-033 is an oral, donor-derived Microbiome Ecosystem Therapy™ being developed by MaaT Pharma. It is a standardized, high-richness, and high-diversity product created using a "pooling" technology that combines donations from multiple healthy donors. The therapy, formulated as a delayed-release capsule, contains a group of anti-inflammatory bacterial species known as Butycore™. The proposed mechanism involves restoring the gut microbiome's diversity and function, which in turn is believed to modulate the immune system. MaaT-033 has been investigated as an adjunctive therapy to improve survival in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for blood cancers and has also shown potential in slowing disease progression in amyotrophic lateral sclerosis (ALS) by targeting the gut-brain axis. The European Medicines Agency (EMA) has granted it Orphan Drug Designation for its use in allo-HSCT.

Other names: pooled allogeneic fecal microbiotherapy

Beyond the preview

Go deeper on MaaT-033.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MaaT-033.

Explore the full profile